In vitro cytotoxicity studies of the pan-BCL-2 family inhibitor obatoclax demonstrated efficacy of this agent against a panel of MLL-r infant leukemias as well as MLL-r cell lines (165, 226); obatoclax also synergized with multiple standard chemotherapeutic agents (226). The gene discussed is KMT2A; the disease is leukemia.